Business Context and Reporting Period
This Form 8-K Current Report, dated April 9, 2019, covers Pacira BioSciences, Inc. (formerly Pacira Pharmaceuticals, Inc.). The filing reports the completion of a strategic acquisition and a corporate name change effective on the same date.
Key Financial Metrics and Transaction Details
- Acquisition Consideration: Approximately $120.0 million in cash, subject to customary post-closing purchase price adjustments and indemnification obligations.
- Milestone Payments: Up to an aggregate of $100.0 million contingent on achieving specific regulatory and commercial milestones.
- Payment Structure: Up to 50% of one 2020 milestone payment may be paid in Pacira common stock at the option of the securityholders.
- Funding Source: The acquisition is funded entirely from cash on hand.
- Escrow: A portion of the merger consideration is held in escrow to secure indemnification obligations.
Material Changes
- Asset Acquisition: Completed the acquisition of MyoScience, Inc., which became a wholly-owned subsidiary of Pacira.
- Corporate Name Change: Changed the corporate name from "Pacira Pharmaceuticals, Inc." to "Pacira BioSciences, Inc."
- Stock Trading: Common stock continues to trade under the ticker symbol "PCRX" on The Nasdaq Global Select Market with no change to the CUSIP number.
Outlook, Risks, and Contingencies
- Future Obligations: The company faces potential future cash outflows of up to $100.0 million if MyoScience achieves defined regulatory and commercial milestones.
- Financial Reporting: Audited financial statements of MyoScience and pro forma financial information reflecting the acquisition are not included in this filing. They are scheduled to be filed by amendment within 71 calendar days.
- Indemnification: The transaction includes indemnification obligations from MyoScience securityholders, secured by escrowed funds.
Investor Verification Checklist
- Verify the final purchase price after customary post-closing adjustments.
- Review the specific regulatory and commercial milestones required to trigger the $100.0 million in potential future payments.
- Monitor the upcoming filing (within 71 days) for MyoScience's audited financial statements and pro forma financial data.
- Confirm the impact of the acquisition on Pacira's cash reserves and liquidity position.